On Saturday, December 3, 2016, Beyond Type 1 and the Diabetes Research Institute Foundation hosted “Beyond Basel” a cocktail party and art exhibition during Art Basel Miami 2016.
The evening brought together 250 members of the Beyond Type 1 and the DRIF communities, featuring works by artists living with Type 1: Appleton (known for his Diabetes-inspired street art featuring needles and insulin bottles), Natalie Irish (famed for painting with her lips on canvas) and tattoo artist Darren Brass (of Miami Ink fame). The winners of the “Express Yourself” Art Contest (Michael Natter, Josh Cooper, Camilla Jacobs and Maureen “Mo” Regulinski) were also on display.
The team at Soho Beach House were outstanding, turning the rooftop deck into an intimate celebration oasis amidst one of Miami’s most dynamic weeks of the year, allowing us to continue to disrupt this disease while creating an organic cultural conversation. The evening also featured an auction, with a chance for guests to win original artwork, a custom tattoo with Darren Brass, a guitar autographed by Nick Jonas, brunch at home by Sam Talbot and a unique experience with NBA superstar Ray Allen.
Special thanks to our Host Committee: Shannon + Ray Allen, Arlene + Wayne Chaplin, Claudine DeNiro, Sabrina Gallo, Amy + Scott Greenwald, Andria + Javier Holtz, Maria + Sheldon Lowe, Sarah Lucas, Marla + Robert Oringer and Deborah + Scott Robins.
ABOUT DIABETES RESEARCH INSTITUTE AND FOUNDATION: The mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As the largest and most comprehensive research center dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production and normalizing blood sugar levels without imposing other risks. Researchers have already shown that transplanted islet cells allow patients to live without the need for insulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes by developing a DRI BioHub, a bioengineered “mini organ” that mimics the native pancreas. While various BioHub platforms are being tested in preclinical and clinical studies, the DRI is also developing strategies to eliminate the need for anti-rejection drugs and reset the immune system to block autoimmunity.